Lymph node staging with fluorine-18 prostate specific membrane antigen 1007-positron emission tomography/computed tomography in newly diagnosed intermediate- to high-risk prostate cancer using histopathological evaluation of extended pelvic node dissection as reference-Reference-Cited by-同舟云学术

Lymph node staging with fluorine-18 prostate specific membrane antigen 1007-positron emission tomography/computed tomography in newly diagnosed intermediate- to high-risk prostate cancer using histopathological evaluation of extended pelvic node dissection as reference

Published:2022-05-11 Issue:11 Volume:49 Page:3929-3937
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Hermsen Rick,Wedick Esmée B. C.^ORCID,Vinken Maarten J. M.,van Kalmthout Ludwike W. M.,Küsters-Vandevelde Heidi V. N.,Wijers Charlotte H. W.,Somford Diederik M.,van Basten Jean-Paul A.

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging,General Medicine,Radiology, Nuclear Medicine and imaging,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00259-022-05827-4.pdf

Reference21 articles.

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

2. Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, Matveev VB, Moldovan PC, van den Bergh RCN, Van den Broeck T, van der Poel HG, van der Kwast TH, Rouvière O, Schoots IG, Wiegel T, Cornford P. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71(4):618–29.

3. Bianchi L, Gandaglia G, Fossati N, Suardi N, Moschini M, Cucchiara V, Bianchi M, Damiano R, Schiavina R, Shariat SF, Montorsi F, Briganti A. Pelvic lymph node dissection in prostate cancer: indications, extent and tailored approaches. Urologia. 2017;84(1):9–19.

4. Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, Rutherford N, Martin JM, Frydenberg M, Shakher R, Wong LM, Taubman K, Ting Lee S, Hsiao E, Roach P, Nottage M, Kirkwood I, Hayne D, Link E, Marusic P, Matera A, Herschtal A, Iravani A, Hicks RJ, Williams S, Murphy DG; proPSMA Study Group Collaborators. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208–16.

5. Pienta KJ, Gorin MA, Rowe SP, Carroll PR, Pouliot F, Probst S, Saperstein L, Preston MA, Alva AS, Patnaik A, Durack JC, Stambler N, Lin T, Jensen J, Wong V, Siegel BA, Morris MJ. A phase 2/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET/CT with 18F-DCFPyL in prostate cancer patients (OSPREY). J Urol. 2021;206(1):52–61.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The association of quantitative PSMA PET parameters with pathologic ISUP grade: an international multicenter analysis;European Journal of Nuclear Medicine and Molecular Imaging;2024-08-01

2. To see clear is not enough; it is the action that counts;Translational Andrology and Urology;2024-03

3. De-Escalation of Therapy for Prostate Cancer;American Society of Clinical Oncology Educational Book;2024-01

4. Head-to-Head Comparison of 18F-PSMA-1007 Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging with Whole-mount Histopathology as Reference in Localisation and Staging of Primary Prostate Cancer;European Urology Oncology;2023-12

5. Subnodal Correspondence of PSMA Expression and USPIO-MRI in Metastatic Pelvic Lymph Nodes in Prostate Cancer;Investigative Radiology;2023-11-17